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SUMMARY – The aim of our study was to measure and compare serum insulin-like growth 
factor-1 (IGF-1) levels at postmenstrual age of 33 weeks between preterm infants with and without 
retinopathy of prematurity (ROP). ROP occurs in two phases. Low serum levels of IGF-1 during 
ROP phase 1 have been found to correlate with the severity of ROP. ROP phase 2 begins around 
postmenstrual week 33. We conducted a prospective cohort study to measure serum IGF-1 levels 
in premature infants at postmenstrual age of 33 weeks. The study included all premature infants 
(N=74), gestational age ≤33 weeks, hospitalized at Department of Neonatology, Clinical Center of 
Montenegro, from April 2008 to July 2009. The incidence of ROP in the study cohort was 50.7%. 
Infants with ROP had a significantly lower birth weight and significantly shorter gestational age. 
The mean level of IGF-1 at postmenstrual age of 33 weeks was 23.7 mcg/L. Study results showed 
that there was no significant difference in serum IGF-1 level between newborns with and without 
ROP at postmenstrual age of 33 weeks (in newborns with ROP, it was the beginning of ROP phase 
2). A large controlled study with repeated measurement of IGF-1 level in the neonatal period is 
needed to confirm that restoration of IGF-I level occurs in ROP phase 2, i.e. that the low level of 
IGF-1 is only a feature of ROP phase 1.
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Introduction
Retinopathy of prematurity (ROP) is a disease of 
preterm infants. It is a serious vasoproliferative dis-
order of immature retinal blood vessels. ROP is the 
most common cause of blindness in childhood in de-
veloped countries1.
The incidence of ROP in the total population of 
preterm infants is 4.2%. In Montenegro, ROP inci-
dence was 3.9% in 2005, 7.9% in 2006, 9.2% in 2007, 
and 12.1% in 20082. The incidence of ROP is signifi-
cantly higher, up to 50%, in preterm infants with ex-
tremely small birth weight (BW).
ROP is a pathologic process that occurs only in 
immature retinal tissue and can progress to tractional 
retinal detachment, which can result in functional or 
complete blindness. In infants born preterm, the ret-
ina is not fully vascularized. The more premature the 
child, the larger is the avascular area. 
During the third trimester, normal retinal vascu-
larization is stimulated by ”physiological hypoxia”3. 
In response to hypoxia, vascular endothelial growth 
factor (VEGF) is secreted. For appropriate VEGF in-
duced vessel growth, sufficient levels of insulin-like 
growth factor-1 (IGF-1) in serum are necessary4.
IGF-1 is a peptide which is essential for both pre-
natal and postnatal growth of retinal vasculature. 
During fetal life, IGF-1 is secreted in most tissues, 
mostly in placenta. In the eye, IGF-1 mRNA was 
found in the sclera and cornea of fetuses aborted at 16-
20 weeks of gestation5. After birth, IGF-1 is produced 
in most organs, mainly in the liver6. Serum levels are 
closely related to gestational age and are lower in more 
prematurely born infants7. Low serum levels of IGF-
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1 during the early postnatal days have been found to 
correlate with the severity of ROP8.
ROP occurs in two phases. The ischemic phase 
1 begins after premature birth with delayed retinal 
vascular growth. The reason for this are low values 
of IGF-1 after preterm birth because of the loss of 
IGF-1 sources from the placenta 7. The proliferative 
phase 2 is characterized by pathologic neovascular-
ization. This leads to ROP phase 2, occurring around 
postmenstrual week 33. When ROP phase 2 is initi-
ated, IGF-1 level reaches the threshold and if VEGF 
is high, neovascularization proliferation proceeds9. If 
the process continues, proliferation advances, blood 
vessels grow in corpus vitreum, which precedes partial 
or total retinal detachment8. This condition is known 
as retrolental fibroplasia (RLF).
The aim of our study was to measure and compare 
serum IGF-1 levels between preterm infants with and 
without ROP at postmenstrual age of 33 weeks. In 
preterm infants with ROP, postmenstrual age of 33 
weeks is the time when ROP phase 2 begins.
Material and Methods 
The study was designed as a cohort, prospective, 
longitudinal type, based on other similar studies. The 
study included all premature infants (N=74), gesta-
tional age ≤33 weeks, hospitalized at Department of 
Neonatology, Clinical Center of Montenegro, from 
April 2008 to July 2009. This study did not include 
infants with conspicuous congenital anomalies.
A database was formed with demographic data, 
data from pregnancy and delivery medical history (the 
course of delivery, evaluation of vitality at birth, an-
thropometric measures at birth), and data from clini-
cal monitoring of the newborn.
In every newborn included in the study, venous 
blood sample (0.5 mL) was obtained in 33rd postmen-
strual week. Extracted serum was frozen and stored 
in a freezer (at -20 up to -80 ºC) until completion 
of a series of samples. In all samples, quantitative de-
termination of the requested biomarkers (IGF-1) was 
performed simultaneously, under the same conditions, 
using immunochemical enzyme-linked immunosor-
bent assay (ELISA), a method widely used on this 
hormone measurement10. 
The diagnosis of ROP was made by ophthalmic 
screening. The infants were examined according to a 
routine protocol, which consisted of dilated eye fun-
dus examinations. After pupillary dilatation, the eyes 
were examined by indirect ophthalmoscopy. ROP was 
classified according to the international classification 
(ICROP) and subdivided into 5 stages. Proliferative 
retinopathy was defined as stage 3, stage 4 or stage 5 
and moderate ROP as stage 1 or stage 2. After getting 
information about the existence of the active form of 
proliferative ROP, the primary cohort (74 newborns) 
was divided into two subgroups: newborns with ROP 
and newborns without ROP.
Ethics Committee of the Clinical Center of Mon-
tenegro in Podgorica approved the study protocol 
(consent number 03/01-3813/4), in accordance with 
standard operating procedures of the Ethics Com-
mittee of the Clinical Center of Montenegro and in-
ternational guidelines for performance of biomedical 
research on humans. 
Statistical data processing included calculation of 
descriptive measures, use of statistical tests and statis-
tical software programs (NCSS, SPSS), for compari-
sons of parameters between the subgroups. The fol-
lowing statistical tests were used: t-test, χ2-test, and 
Pearson’s correlation test.  
Results    
Primary cohort included 74 preterm infants of 
gestational age (GA) ≤33 weeks. There were 42 
(56.8%) male and 32 (43.2%) female newborns. Table 
1 shows the structure of primary cohort according to 
the history of pregnancy (singleton or multiple) and 
type of delivery (vaginal or cesarean section).
Of the total number of newborns in primary co-
hort, 95.9% (n=71) were tested for ROP (ophthalmic 
Table 1. Distribution of newborns according to pregnancy 
and delivery history data
Without ROP With ROP
Pregnancy
Singleton 23 (47.9%) 25 (52.1%)
Multiple 12 (52.2%) 11 (47.8%)
Type of delivery
Vaginal 18 (45.0%) 22 (55.0%)
Cesarean section 17 (54.8%) 14 (45.2%)
ROP = retinopathy of prematurity
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screening). Three (4.1%) newborns were transferred to 
other institutions for further diagnostic work-up and 
therapy, which was the reason for excluding them from 
the process of diagnosing ROP. Through ophthalmic 
screening, 36 (48.7%) newborns were diagnosed with 
proliferative form of ROP, whereas 35 newborns had 
normal ophthalmologic findings.  
The mean birth weight (BW) of newborns in pri-
mary cohort was 1698.24±402.79g (range 990-2860 
g). Table 2 shows mean BW of newborns with and 
without ROP. Student’s t-test revealed the difference 
in the mean BW between newborns with and without 
ROP to be statistically significant, with negative di-
rection (t=-2.50; p<0.05). Newborns with ROP had a 
significantly lower BW. 
Figure 1 shows distribution of newborns from pri-
mary cohort according to GA. The mean GA in pri-
mary cohort was 31.18±1.87 (range 26-33) gestational 
weeks. Table 2 shows mean GA of newborns with and 
without ROP. Student’s t-test showed the difference 
in the mean GA between newborns with and without 
ROP to be statistically significant, with a negative di-
rection (t=-2.76; p<0.01). Newborns with ROP had a 
significantly shorter GA at birth.   
Out of 36 newborns with ROP, 20 (55.6%) were 
male and 16 (44.4%) female. Figure 2 shows distribu-
tion of male and female newborns according to mor-
bidity from ROP. Pearson χ2-test showed that there 
was no statistically significant difference in the fre-
quency of ROP between male and female newborns 
(χ2=0.12; p>0.05).   
The mean level of IGF-1 in primary cohort was 
23.74±5.79 mcg/L (range 15.44-46.33). In 19 (25.7%) 
newborns, the level of IGF-1 was lower than 20 
mcg/L, in 33 (44.6%) newborns it was 20-25 mcg/L, 
and 21 (28.4%) newborns had IGF-1 above 25 mcg/L. 
The mean postnatal age at sampling was 12.56±11.97 
days (range 1-56).  
On average, male newborns had a lower level of 
IGF-1 (23.16±4.98 mcg/L) than female newborns 
(24.49±6.73 mcg/L). Pearson’s correlation test yielded 
no significant correlation between sex and level of 
IGF-1 in 33rd postmenstrual week (p=0.07; p>0.05).  
Table 2 shows mean levels of IGF-1 in newborns 
with and without ROP. Student’s t-test showed no 
statistically significant difference in the mean levels 
Table  2. Distribution of newborns according to birth weight (BW), gestational age (GA) and levels of insulin-like 
growth factor-1 (IGF-1) in relation to the presence of retinopathy of prematurity (ROP)
Finding        Parameter
                                BW (g)                              GA (weeks) IGF (mcg/L) 
χ SD χ SD χ SD
Without ROP 1821.71 369.59 31.8 1.43 23.79 4.85
With ROP 1586.94 417.99 30.61 2.12  23.88 6.74
Significance t=-2.50 p<0.05 t=-2.76 p<0.01 t=0.05 p>0.05
Fig. 1. Distribution of newborns from the primary cohort 
according to gestational age (weeks).
Fig. 2. Distribution of male and female newborns accord-
ing to morbidity from retinopathy of prematurity (ROP). 
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of serum IGF-1 between newborns with and without 
ROP (t=0.05; p>0.05).     
Pearson χ2-test yielded no significant difference in 
the frequency of ROP between the cohorts of new-
borns with different levels of serum IGF-1 (χ2=1.77; 
p>0.05).
Discussion and Conclusion
Premature birth is the main risk factor for ROP. 
Improved neonatal care has resulted in increased sur-
vival of extremely immature infants at a high risk to 
develop ROP. The increase in the incidence of ROP 
follows the increase in the incidence of blindness. 
Data from neighboring Croatia show that on every 
26th day, one child gets blind because of ROP, add-
ing that in the population of blind children up to 16 
years of age ROP is the main cause of blindness. This 
tells us a lot about the importance of prevention and 
therapy for ROP for the overall health system of every 
country11. Better understanding of the pathophysiol-
ogy of ROP contributes to achieving this goal.
The present study was performed at Department 
of Neonatology, the only center for medical treat-
ment of the endangered preterm and term infants 
in Montenegro. Usually, 65% of the total number of 
preterm newborns in Montenegro are hospitalized 
at this Department. When we started the study in 
2008, there were 8258 children born in Montenegro, 
of which 495 (6%) premature infants. In the same 
year, 860 newborns were hospitalized, of which 255 
(29.6%) preterm, while 60 newborns were diagnosed 
with proliferative ROP and had the indication for la-
ser treatment. In 2008, the incidence of proliferative 
ROP in Montenegro was 12.1%2.
The incidence of proliferative ROP in our primary 
cohort was 50.7%. This high incidence of ROP stems 
from the fact that the participants of our study were 
‘endangered’ preterm infants who, after birth, had to 
be transferred to Department of Neonatology. This 
fact implies the higher presence of risk factors for the 
development of ROP (oxygen therapy, mechanical 
ventilation, anemia, transfusion). 
Study results showed that there was no statistically 
significant difference in the incidence of ROP between 
male and female preterm infants. Newborns with ROP 
had a significantly lower BW and shorter GA at birth. 
The difference in GA was highly significant.
The mean level of serum IGF-1 in primary cohort 
was 23.7 mcg/L, which was also the mean level of 
IGF-1 at postmenstrual age of 33 weeks in endan-
gered preterm infants in Montenegro. Serum IGF-1 
level was slightly lower in male than in female new-
borns, but this difference was not statistically signifi-
cant. In the cohorts formed on the basis of interval 
levels of IGF-1, there was no significant difference in 
the incidence of ROP. 
There was no significant difference in serum IGF-
1 level at postmenstrual age 33 weeks between new-
borns with and without ROP. The level of IGF-1 in 
ROP phase 2 did not differ significantly from the level 
of IGF-1 in newborns of the same postmenstrual age 
without ROP. 
A large controlled study with repeated measure-
ment of IGF-1 level in the neonatal period is needed 
to confirm that restoration of IGF-I level occurs in 
ROP phase 2, i.e. that the low level of IGF-1 is only a 
feature of ROP phase 1.
Several clinical studies have shown that persistent 
low serum concentrations of IGF-I after premature 
birth are associated with later development of ROP9. 
However, some studies have shown that there is no 
significant difference in serum IGF-1 level between 
the proliferative ROP group and non-proliferative 
group in any postnatal period12. 
The possible reason for different results should be 
looked for in rapid nutritional and metabolic changes 
during postnatal life, which have great effect on IGF-
1 level. Future studies should take in consideration 
the effect of nutritional and metabolic status of the 
newborns on serum level of IGF-1. 
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Sažetak 
PREMATURNA RETINOPATIJA I SERUMSKA RAzINA INzULINU SLIČNOG FAKTORA RASTA–1 
L. Banjac i V. Bokan
Cilj rada je bio izmjeriti i usporediti serumsku razinu insulinu sličnog faktora rasta-1 (IGF-1) u 33. postmenstrualnom 
tjednu između prijeterminske novorođenčadi s prematurnom retinopatijom (PR) i bez PR. PR se javlja u dvije faze. Na-
đeno je da je niska serumska razina IGF-1 tijekom prve faze PR u korelaciji s težinom PR. Druga faza PR počinje oko 33. 
postmenstrualnog tjedna. Provedena je kohortna prospektivna studija u kojoj se mjerila serumska razina IGF-1 kod prije-
terminske novorođenčadi u 33. postmenstrualnom tjednu. U studiju su uključena sva prijeterminska novorođenčad (N=74) 
gestacijske starosti ≤33 tjedna koja su bila hospitalizirana u Centru za neonatologiju Kliničkog centra Crne Gore od travnja 
2008. do srpnja 2009. Incidencija PR u studijskoj kohorti iznosila je 50,7%. Novorođenčad s PR imala su značajno nižu 
porođajnu tjelesnu masu i značajno kraću gestacijsku dob. Prosječna razina IGF-1 u 33. postmenstrualnom tjednu iznosila 
je 23,7 mcg/L. Naši rezultati su pokazali da u 33. postmenstrualnom tjednu (za novorođenčad s PR to je početak druge 
faze PR) nema značajne razlike u serumskoj razini IGF-1 između novorođenčadi s PR i bez PR. Potrebno je provesti veću 
kontroliranu studiju s ponavljanim mjerenjem razine IGF-1 u neonatalnom razdoblju kako bi se potvrdilo da u drugoj fazi 
PR dolazi do restitucije razine IGF-1, odnosno da je niska razina IGF-1 odlika samo prve faze PR.
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